Ferring Pharmaceuticals concluded a Phase II trial in 2014. The goal of the study was to evaluate the safety and effectiveness of an intranasal oxytocin analogue in treating hyperphagia in children and young adults with Prader-Willi Syndrome. Participants were between the ages of 10-18, in nutritional phase 3, and with a genetic confirmation of PWS.
No matter how big or how small, every effort helps us!
The Foundation for Prader-Willi Research (federal tax id 31-1763110) is a nonprofit corporation with federal tax exempt status as a public charity under section 501(c)(3).
The mission of FPWR is to eliminate the challenges of Prader-Willi syndrome through the advancement of research and therapeutic development.
Copyright © 2020. All Rights Reserved. Terms of Use. Privacy Policy. Copyright Infringement Policy. Disclosure Statement.
